Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms

Abstract

Checkpoint inhibitor therapy shows limited activity in patients with NENs. Future studies should identify biomarkers that can help identify patients who are likely responders to immunotherapy.